Literature DB >> 3134043

Fibrinolysis during normal human pregnancy: complex inter-relationships between plasma levels of tissue plasminogen activator and inhibitors and the euglobulin clot lysis time.

J G Wright1, P Cooper, B Astedt, I Lecander, J T Wilde, F E Preston, M Greaves.   

Abstract

Although it has been previously considered that blood fibrinolytic capacity is reduced during pregnancy, this has been disputed. Also the mechanisms underlying any change in fibrinolysis in pregnancy require clarification. We have therefore measured the plasma activity of tissue plasminogen activator (t-PA) and inhibitors (t-PAi) and the concentration of the pregnancy specific inhibitor (PA12) antigen, as well as the euglobulin clot lysis time (ECLT) during normal pregnancy. Plasma concentrations of fibrinogen, plasminogen, fibrin(ogen) degradation products (FDP) and cross-linked products (D-dimer) were also monitored. We confirm a marked reduction of the fibrinolytic activity of the plasma euglobulin fraction from the second trimester, and a parallel reduction in t-PA and increase in t-PAi activities, with rapid return to non-pregnant levels post-partum. In contrast, PAI2, whilst undetectable in non-pregnant control plasma, was already measurable in the first trimester, increased through pregnancy, and remained at a high concentration up to at least 48 h post-partum. Fibrinogen and plasminogen concentrations rose progressively through pregnancy and FDP and D-dimer were frequently detectable in late pregnancy plasma. Changes in the ECLT and plasma t-PA and t-PAi activities in pregnancy cannot therefore be directly related to the concentration of PAI2 antigen. Also, despite the apparent marked reduction in fibrinolytic capacity fibrin(ogen) breakdown products are frequently present in increased plasma concentrations in late pregnancy.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3134043     DOI: 10.1111/j.1365-2141.1988.tb07630.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  4 in total

1.  The cost-benefit ratio of screening pregnant women for thrombophilia.

Authors:  Gian Luca Salvagno; Giuseppe Lippi; Massimo Franchini; Giovanni Targher; Martina Montagnana; Massimo Franchi; Gian Cesare Guidi
Journal:  Blood Transfus       Date:  2007-11       Impact factor: 3.443

2.  An anticoagulant dermatan sulfate proteoglycan circulates in the pregnant woman and her fetus.

Authors:  M Andrew; L Mitchell; L Berry; B Paes; M Delorme; F Ofosu; R Burrows; B Khambalia
Journal:  J Clin Invest       Date:  1992-01       Impact factor: 14.808

3.  The pattern and magnitude of "in vivo thrombin generation" differ in women with preeclampsia and in those with SGA fetuses without preeclampsia.

Authors:  Offer Erez; Roberto Romero; Edi Vaisbuch; Juan Pedro Kusanovic; Shali Mazaki-Tovi; Tinnakorn Chaiworapongsa; Francesca Gotsch; Pooja Mittal; Samuel S Edwin; Chia-Ling Nhan-Chang; Nandor Gabor Than; Chong Jai Kim; Sun Kwon Kim; Lami Yeo; Moshe Mazor; Sonia S Hassan
Journal:  J Matern Fetal Neonatal Med       Date:  2017-05-23

4.  Relationship Between Estradiol and Hemostasis Determined Through Thromboelastography Profile in Controlled Ovarian Stimulation Cycles.

Authors:  Wiryawan Permadi; Mulyanusa Amarullah Ritonga; Hartanto Bayuaji; Niswan Helja; Corina Delarosa Khoirunnisa; Tono Djuwantono
Journal:  J Blood Med       Date:  2021-05-27
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.